We have recently described a class of peptides that improve drug delivery by increasing penetration of drugs into solid tumors. These peptides contain a C-terminal Cend Rule (CendR) sequence motif (R/K)XX(R/K), which is responsible for cell internalization and tissue-penetration activity. Tumor-specific CendR peptides contain both a tumor-homing motif and a cryptic CendR motif that is proteolytically unmasked in tumor tissue. A previously described cyclic tumor-homing peptide, LyP-1 (sequence: CGNKRTRGC), contains a CendR element and is capable of tissue penetration. We use here the truncated form of LyP-1, in which the CendR motif is exposed (CGNKRTR; tLyP-1), and show that both LyP-1 and tLyP-1 internalize into cells through the neuropilin-1-dependent CendR internalization pathway. Moreover, we show that neuropilin-2 also binds tLyP-1 and that this binding equally activates the CendR pathway. Fluorescein-labeled tLyP-1 peptide and tLyP-1-conjugated nanoparticles show robust and selective homing to tumors, penetrating from the blood vessels into the tumor parenchyma. The truncated peptide is more potent in this regard than the parent peptide LyP-1. tLyP-1 furthermore improves extravasation of a co-injected nanoparticle into the tumor tissue. These properties make tLyP-1 a promising tool for targeted delivery of therapeutic and diagnostic agents to breast cancers and perhaps other types of tumors.
Introduction
Targeted delivery of therapeutic or diagnostic agents to tumors constitutes a major goal in cancer treatment. By increasing the amount of a drug reaching the tumor, the efficacy is improved while side effects are reduced. This strategy relies on the identification of the molecular signature of tumor vessels, and development of specific affinity ligands to carry payloads to the tumor (Ruoslahti, 2002a, b) . Nanoparticles can be used to further improve drug delivery and efficacy by incorporating multiple functions and increasing the payload (Ruoslahti et al., 2010) . However, dysfunctional tumor blood vessels and high interstitial pressure tend to prevent penetration of drugs and nanoparticles into the tumor tissue, limiting the efficacy of the treatments (Jain, 1999; Heldin et al., 2004) .
We have recently described a technology that provides a way to overcome the limited tissue penetration. C-end Rule (CendR) peptides induce extravasation and tissue penetration via a mechanism that involves cell internalization Teesalu et al., 2009) . CendR peptides are defined by the presence of the motif (R/K)XX(R/K) (X represents any amino acid), which has to be at the C-terminus for the cell-and tissue-penetration activity. The receptor for the CendR motif was shown to be neuropilin-1 (NRP1) .
NRP1 is a modular transmembrane protein previously identified as a receptor for various forms and isoforms of VEGF (vascular endothelial growth factor) and members of the class 3 semaphorin family (Takagi et al., 1987; He and Tessier-Lavigne, 1997; Kolodkin et al., 1997; Soker et al., 1998) . Neuropilin-2 (NRP2), the second member of the neuropilin family, exhibits sequence and structure homology with NRP1, and shares common ligands, among them VEGFA 165 (Chen et al., 1997; Kolodkin et al., 1997; Gluzman-Poltorak et al., 2000) . However, there are also ligands that show selective affinity for one or the other NRP (Chen et al., 1997; Gluzman-Poltorak et al., 2000) . Moreover, NRP1 and NRP2 display different expression patterns, with NRP2 (but not NRP1) overexpressed in tumor lymphatics (Caunt et al., 2008) . In the CendR pathway, NRP1 appears to be essential for cell internalization and tissue penetration , whereas the role of NRP2 has not been investigated.
Binding to NRP1 requires an exposed C-terminal CendR motif, and peptides with an embedded binding motif in their sequence depend on proteolytic cleavage to activate the CendR internalization pathway. The recently described tumor-penetrating peptide iRGD follows this two-step mechanism. Indeed, iRGD contains an RGD motif for recruitment to angiogenic blood vessels and a cryptic CendR motif that is proteolytically unmasked in tumor to trigger extravasation and tissue penetration . As a result of the proteolytic cleavage, iRGD loses its affinity for the integrins, acquires NRP1-binding capacity and induces extravasation . Importantly, co-injected drugs or particles penetrate inside the tumor parenchyma along with iRGD, allowing an increase of treatment efficacy in a number of different cancer models .
Similar to iRGD, LyP-1 is a tumor-homing cyclic nonapeptide, which contains a cryptic CendR motif (sequence: CGNKRTRGC), and was identified in our laboratory by phage display (Laakkonen et al., 2002) . LyP-1 homes to tumor lymphatics, tumor cells and tumor macrophages by specifically binding to its receptor p32, a mitochondrial protein expressed on the surface of these cells (Laakkonen et al., 2002; Fogal et al., 2008) . LyP-1 also homes to atherosclerotic plaques and penetrates into their interior (Hamzah et al., 2011; Uchida et al., 2011) . The presence of the cryptic CendR motif suggests the possibility of secondary binding to NRP1 (and perhaps to NRP2 in the lymphatics) and involvement of the CendR pathway. This hypothesis is supported by previous studies showing that LyP-1 is able to extravasate and penetrate the tumor parenchyma (Laakkonen et al., 2002; von Maltzahn et al., 2008; Karmali et al., 2009) .
Here, we investigate LyP-1 internalization pathway, and characterize a new peptide derived from LyP-1, with an active CendR element for tumor targeting.
Results

LyP-1 is a cryptic CendR peptide
In order to investigate the role of the CendR motif in LyP-1 peptide, we tested the binding of phage displaying the predicted active CendR fragment CGNKRTR (tLyP-1, for truncated LyP-1) and other truncated forms of LyP-1 to cultured tumor cells. We used DU145 prostate carcinoma cells, because they express only NRP1, and not NRP2 (Supplementary Figures S1A and S2A) . As these peptides could have other receptors on the DU145 cells, we used inhibition of cell binding by a function-blocking anti-NRP1 antibody as an indicator of NRP1 dependence of phage binding. The antibody inhibited the cell binding of the phage expressing RPARPAR, the prototypic CendR peptide, by about 70% (Figure 1a) . A similar degree of inhibition was obtained for the phage tLyP-1. The NRP1 antibody did not significantly inhibit the binding of the other truncated forms of LyP-1 (Figure 1b ). Thus, a single or double basic residue at the C-terminus, as in CGNK or CGNKR, was not enough to confer significant ability to bind to NRP1. CGNKRTRG showed a mild reproducible decrease in DU145 cell binding upon anti-NRP1 treatment, suggesting that the presence of the glycine residue C-terminal of the CendR motif may be compatible with NRP1 binding. This is supported by recent modeling studies showing that glycine-containing peptides (G 7 , G 3 RG 3 and G 4 RG 2 ) were able to dock in NRP1-binding pocket without major deformation of the receptor structure (Haspel et al., 2011) . In contrast, the Tumor-penetrating peptide L Roth et al binding of full-length LyP-1 to the cells was not inhibited by the anti-NRP1, suggesting that the peptide has to be processed into its CendR form to be able to bind to NRP1.
We next analyzed the distribution of intravenously administered tLyP-1 phage in normal mice after 15 min circulation, and observed that it showed significant accumulation in the lungs (Figure 1c ). This finding agrees with previously described accumulation of CendR phage in the lungs, presumably because it is the first vascular bed encountered by intravenously injected substances . Taken together, the binding and inhibition results, and the invivo phage distribution strongly suggest that tLyP-1 is an active CendR peptide.
NRP1 binds tLyP-1 phage and mediates its internalization We next tested the binding of tLyP-1 to purified NRP1. The tLyP-1 phage bound to immobilized NRP1 about 120 times more than insertless control phage, whereas phage expressing intact LyP-1 showed no binding ( Figure 2a) . RPARPAR phage exhibited a 280-fold binding ratio over the control phage, suggesting a higher affinity for NRP1 than tLyP-1.
RPARPAR-displaying phage was originally shown to strongly bind to and internalize into cultured PPC1 prostate carcinoma cells , which express high levels of NRP1 (Supplementary Figure  S1A) . We found that tLyP-1 phage had a similar activity, whereas LyP-1 phage did not interact with the PPC1 cells ( Figure 2b ).
As observed with RPARPAR phage, all or almost all the PPC1 cells were positive for tLyP-1 phage uptake. Moreover, tLyP-1 phage co-localized with NRP1 in vesicular structures inside the cells, suggesting that the two proteins co-internalized upon interaction (Figure 2c, arrows) . tLyP-1 internalization into the PPC1 cells was inhibited in a dose-dependent manner by oligomeric RPARPAR peptide (Figure 2d ), further showing that tLyP-1 internalization follows the CendR pathway. Tumor-penetrating peptide L Roth et al NRP2 binds CendR peptides and mediates their internalization NRP2 involvement in the CendR pathway has not been addressed. Given the homology between NRP1 and NRP2, and the similarities in LyP-1 homing and NRP2 tissue and cell distribution, we hypothesized that NRP2 could also be a CendR receptor. Indeed, tLyP-1 phage bound to purified NRP2 about eight times more than insertless phage ( Figure 3a ). As observed for NRP1 binding, RPARPAR phage exhibited higher level of binding to NRP2 than tLyP-1 phage (binding ratios over control ¼ 29 versus 8). The binding of both peptides was higher to NRP1 than to NRP2, suggesting that CendR peptides preferentially bind to NRP1. LyP-1 phage did not bind to NRP2 (binding ratio over control ¼ 0.6). We next studied binding and internalization of phage clones into MDA-MB-435 breast carcinoma cells that express only NRP2, and not NRP1 (Supplementary Figure S1A) . tLyP-1 phage bound and internalized into these cells, where it co-localized with NRP2 (Supplementary Figure S2B ; Figure 3b , arrows). tLyP-1 phage internalization into MDA-MB-435 cells was lower than into PPC1 cells, possibly due to the weaker affinity for NRP2 than for NRP1, or/and to lower total NRP expression in the MDA-MB-435 cells. Using a function-blocking antibody against NRP2, we confirmed that tLyP-1 phage directly bound to NRP2 in MDA-MB-435 cells ( Figure 3c ). The anti-NRP2 antibody also inhibited RPARPAR phage binding, and oligomeric RPARPAR peptide blocked the binding and internalization of phage tLyP-1 in the cells, further demonstrating the role of NRP2 in the CendR pathway ( Figure 3d ).
LyP-1 internalization uses the CendR pathway
The MDA-MB-435 cells express the cell surface LyP-1 primary receptor p32, and LyP-1 internalizes into these cells (Fogal et al., 2008) . To test whether internalization of tLyP-1 and LyP-1 could occur through p32, we explored tLyP-1 capacity to bind to this receptor.
A saturation assay performed with fluorescein-labeled peptides (FAM-peptides) showed low binding of tLyP-1 to purified p32, whereas robust binding was seen with FAM-LyP-1 (Supplementary Figure S3) . Moreover, affinity chromatography of 4T1 breast tumor extracts on tLyP-1 revealed no binding of p32 to the tLyP-1 affinity matrix (data not shown). Thus, only the intact LyP-1 peptide binds to p32. Tumor-penetrating peptide L Roth et al
Having established that (i) tLyP-1 but not LyP-1 binds to NRP1 and NRP2, (ii) LyP-1 but not tLyP-1 binds to p32 and (iii) both LyP-1 and tLyP-1 internalize into MDA-MB-435 cells, we tested the effect of tLyP-1 on LyP-1 cell internalization. Oligomeric tLyP-1 peptide concentration dependently and fully inhibited LyP-1 phage internalization (Figure 3e ). This result supports our hypothesis of a common internalization pathway for LyP-1 and tLyP-1, and the likely cleavage of LyP-1 into the CendR form tLyP-1.
We thus hypothesize that LyP-1 internalization mechanism is very similar to what has been documented for the iRGD peptide ): LyP-1 first binds to cell surface p32 in tumors, which triggers a protease cleavage into the tLyP-1 form, and a shift from p32 to NRP1/2 binding, made possible by the loss of affinity for p32 and newly acquired affinity for the NRPs. The NRP binding then activates the CendR cell internalization pathway (Figure 4 ). Figure S4) . Tumors examined 1 h after the injection of FAM-tLyP-1 were strongly fluorescent under blue light (Figure 5a ). Normal tissues, which express NRP1 at lower levels than tumors (Ellis, 2006; Guttmann-Raviv et al., 2006; Bagri et al., 2009) , were negative, with the exception of the kidneys, which reflects the clearance of the peptide through this organ. A control peptide, FAM-ARALPSQRSR (Laakkonen et al., 2002) , did not accumulate in the 4T1 tumors. Similar results were obtained in human MDA-MB-435 breast cancer xenografts (Figure 5b ). Further confocal microscopy analyses confirmed the selective accumulation of FAM-tLyP-1 in 4T1 tumor tissue, and revealed extensive spreading of the label within the tumor (Figure 5c ).
To evaluate the capability of tLyP-1 to deliver nanoparticles into tumors and penetrate into tumor tissue, we conjugated FAM-tLyP-1 to elongated iron oxide nanoparticles dubbed nanoworms (tLyP-1-NWs; dimensions: 30 Â 80-100 nm) (Park et al., 2009; Agemy et al., 2010) . Iron oxide nanoparticles have the advantage that they can serve as a contrast agent in magnetic resonance imaging. Examination of tLyP-1-NW biodistribution showed specific homing of tLyP-1-NWs to 4T1 tumors ( Figure 6a ). As reported previously for various nanoparticles, the NWs nonspecifically accumulated in the liver and spleen to a small extent (Thorek et al., 2006) , and some were also found in the kidney, presumably reflecting the release of the labeled peptide from the NWs (Supplementary Figure S5) . The accumulation of the NWs in the tumor was observed at all time points studied (from 30 min to overnight circulation) (Figure 6a; Supplementary Figure S5 ). The tLyP-1-NWs also specifically homed to the tumors in a third breast cancer model, human MDA-MB-231 xenografts, which express both NRP1 and NRP2 (Supplementary Figure S6A) .
Comparison of tLyP-1-NWs with LyP-1-NWs and RPARPAR-NWs
The tissue distribution profile of tLyP-1-NW was comparable to that of the parental LyP-1-NW with respect to tumor-specific homing, but their spreading patterns were different (Figure 6a) . After 4 h of circulation, tLyP-1-NWs showed a significantly wider distribution in the tumor tissue than LyP-1-NWs; the fluorescent surface area in the tumor sections was about four times larger in the tLyP-1 tumors (Figure 6b ). The enhanced penetration properties of tLyP-1-NW may be attributable to the exposed CendR motif.
The distribution of the tLyP-1-NWs was strikingly different from NWs coated with the prototypic CendR, RPARPAR. Indeed, besides extensive tumor accumulation, RPARPAR-NWs were also present in each of the other tissues we examined (Figure 6c ). The accumulation of the RPARPAR-NWs in the liver, spleen and kidney was higher than that of tLyP-1-NWs or LyP-1-NWs. In addition, the RPARPAR-NWs were present in the heart, lungs and pancreas, which were negative for tLyP-1-NWs. Thus, tLyP-1, even though it is an active CendR peptide, is a specific tumor-homing peptide, possibly because of its lower affinity for NRP receptors compared with RPARPAR. Figure 4 LyP-1 is a cryptic CendR peptide. Cyclic LyP-1 concentrates at the surface of tumor cells by binding to its primary receptor p32. LyP-1 is then proteolytically cleaved into the linear truncated form, tLyP-1, which diminishes its affinity for p32. The exposed C-terminal CendR motif becomes active and triggers binding to NRP1 and/or NRP2, and subsequent cell internalization.
Tumor-penetrating peptide L Roth et al Tumor-penetrating peptide L Roth et al tLyP-1-NWs extravasate into regions positive for NRP1 and NRP2 and tLyP-1 peptide increases tumor penetration of a co-injected compound To assess tLyP-1-NWs tumor penetration over time, tumor sections were analyzed after different circulation times, and blood vessels were stained with an anti-CD31 antibody (Figure 7a ). After 30 min of circulation, tLyP-1-NWs fluorescence co-localized to a high extent with the CD31 staining, showing that the NWs were mainly inside the blood vessels or associated with the blood vessel walls. After 4 h, most of the NWs had extravasated and penetrated the tumor tissue, with only a small fraction still associated with the blood vessels. Similar extravasation pattern was also observed in MDA-MB-231 breast cancer xenografts (Supplementary Figure S6B) . tLyP-1-NWs were present in tumor regions where NRP1 and NRP2 were abundantly expressed, and co-localization with anti-NRP1 and anti-NRP2 immunostaining was observed (Figure 7b , arrows). tLyP-1-NWs were still seen in the tumor after overnight circulation, whereas the nonspecific accumulation in the liver, spleen and kidney was no longer detectable (Supplementary Figure S5) . For this time point, the tLyP-1-NW signal no longer co-localized with tumor blood vessels and had spread deeper through the tumor tissue. We also tested the ability of tLyP-1 to trigger tumor penetration of a co-administered compound by activating the CendR pathway Sugahara et al., 2010) . We injected tLyP-1 peptide together with NWs coated with a tumor-homing peptide (sequence: CGKRK) that is unable to get out of the blood vessels by itself (Hoffman et al., 2003; Agemy et al., 2011) . Confocal microscopy analyses revealed enhanced tumor penetration of CGKRK when injected with tLyP-1 (Figure 7c) . Thus, tLyP-1 can also induce penetration of a co-administered compound.
Discussion
Our results show that the tumor-homing peptide LyP-1 (Laakkonen et al., 2002) uses the CendR mechanism for cell internalization. More importantly, we document a novel tumor-homing peptide, tLyP-1, which exhibits enhanced penetration capacity within tumor tissue compared with full-length LyP-1, even when tethered Tumor-penetrating peptide L Roth et al on nanoparticles. This peptide is furthermore able to induce penetration of a co-injected substance. A strong body of evidence links LyP-1 to the CendR pathway Teesalu et al., 2009) . First, we show that exposure of the CendR motif in LyP-1 triggers binding to the established CendR receptor, NRP1. Second, we show that this binding is specific, and follows the CendR rule-the CendR motif 'KRTR' must possess a free C-terminus for the binding to occur. Third, we show that when the CendR motif is exposed, the phage is internalized into cells, where it co-localizes with NRP1. Inhibition of the internalization by the prototypic CendR RPARPAR confirmed the involvement of the CendR pathway. These results strongly suggest that the tumor-penetrating properties of LyP-1 depend on the exposure of the cryptic CendR motif.
The previously identified cryptic CendR peptide, iRGD, loses its affinity for the primary tumor receptor av integrin after proteolytic cleavage and acquires affinity for NRP1 . Similarly, the LyP-1 CendR fragment, tLyP-1, exhibited a weak affinity for the primary receptor p32, suggesting that cryptic CendR peptides follow a general pattern involving loss of affinity for the primary receptor after cleavage, and acquisition of an affinity for NRP1. Hence, the full inhibition of LyP-1 internalization by the CendR fragment tLyP-1 likely indicates that internalization occurs through NRP, and not through p32, even though we cannot entirely rule out the participation of other binding molecules.
VEGFA 165 , which induces vascular permeability through its interaction with NRP1 (Becker et al., 2005; Mamluk et al., 2005; Acevedo et al., 2008) , binds to NRP2 as well (Soker et al., 1998; Gluzman-Poltorak et al., 2000) . Interestingly, using cancer cell lines that express selectively one or the other NRP, we were able to show that NRP2 is also a receptor for CendR peptides, although with a lower binding capacity compared with NRP1. NRP2 is expressed in tissues and cells where NRP1 is absent. Thus, ability to bind NRP2 might be crucial for penetration of CendR peptides in these specific tissues, an example of which may be tumor lymphatics, which express high levels of NRP2 and are a specific target of LyP-1 (Laakkonen et al., 2002 (Laakkonen et al., , 2004 . The distinct properties of various CendR peptides therefore increase the targeting possibilities offered by this technology.
The most significant and surprising finding in this study was the specific homing of the CendR fragment tLyP-1 to tumors, and its high penetration characteristics. The poor quality and leakiness of tumor vessels can cause extravasation and retention of materials in tumors (Greish, 2007) . However, our results show that the accumulation of FAM-tLyP-1 in the tumors is specific. The tLyP-1 peptide alone or conjugated to nanoparticles specifically homed to three different types of breast tumors, and spread widely within the tumor tissue. This significantly enhanced penetration compared with LyP-1 nanoparticles is likely due to the direct exposure of the CendR motif and the absence of proteolytic activity requirement. tLyP-1 was also able to induce co-penetration of CGKRK-NWs, which do not extravasate when injected alone, further demonstrating that it exhibits CendR characteristics in vivo.
tLyP-1 showed more specific homing properties than the prototypic CendR peptide RPARPAR. RPARPAR nanoparticles accumulated in all organs analyzed, which is related to its capacity to induce extravasation and tissue penetration through NRP1 binding . In contrast, tLyP-1 only accumulated in tumors, both as a free peptide and on nanoparticles. Possible reasons for this difference include the lower affinity of tLyP-1 for NRPs, which should favor binding to tissues with the highest local concentration of NRPs, the tumors (Bagri et al., 2009) . It is also possible that NRPs are at a higher state of activation in tumors than in normal tissues; regulation of receptor activation is a well-documented phenomenon with other receptors (for example, integrins; Hynes, 2002) . Enhanced neuropilin activation could accentuate the effects of the affinity difference between RPARPAR and tLyP-1.
The high expression of both NRP1 and NRP2 in tumors allows one to envision applications for tLyP-1 in tumor targeting. In this study, we show homing and penetration of tLyP-1 to tumors in three different breast cancer models with different patterns of cancer cell NRP expression. Moreover, NRP1 and NRP2 are also present in tumor vessels, where NRP1 is involved in angiogenesis, and NRP2 in lymphangiogenesis Pan et al., 2007; Caunt et al., 2008; Dallas et al., 2008) . Thus, tLyP-1 may be useful in targeting a variety of solid tumors and to deliver therapeutic or diagnostic agents deep inside the tumor tissue. As a proof of principle, we have shown here that tLyP-1 was able to carry fluorescein and superparamagnetic iron oxide nanoparticles to the tumor interior. Moreover, tLyP-1 induced co-penetration of NWs conjugated with a tumor-homing peptide from tumor blood vessels to the tumor parenchyma. Previous studies with another tumor-penetrating peptide, iRGD, have demonstrated the efficacy of these strategies in tumor treatment and imaging . Thus, the strong tumor-homing and penetrating properties of tLyP-1 make it a potentially important addition to the arsenal of targeting agents for drug delivery.
Materials and methods
Antibodies and purified proteins Purified proteins were used for phage binding assays: recombinant human NRP1 (R&D, Minneapolis, MN, USA) and recombinant human NRP2 Fc chimera (R&D). The ligand-blocking polyclonal antibodies, goat anti-rat NRP1 and goat anti-human NRP2, were purchased from R&D. Goat IgG (AbCam, Cambridge, MA, USA) was used as control. For immunofluorescence, the primary antibodies were (i) monoclonal rat anti-mouse CD31 (BD Biosciences, San Diego, CA, USA), (ii) polyclonal rabbit anti-human NRP1 (Chemicon, Temecula, CA, USA), (iii) polyclonal rabbit anti-human NRP2 (Novus Biologicals, Littleton, CO, USA) and (iv)
Tumor-penetrating peptide L Roth et al polyclonal rabbit anti-T7 phage . The following secondary antibodies were used: donkey anti-goat 488/546, goat anti-rat 546 and goat anti-rabbit 488/546 (Invitrogen, Carlsbad, CA, USA).
Cell lines and tumors MDA-MB-435 (Fogal et al., 2008) , DU145 (purchased from ATCC, Manassas, VA, USA) and PPC1 ) cells were cultured in Dulbecco's modified eagle medium (Gibco) and 4T1 cells (purchased from ATCC) in IMDM (Gibco). Media were supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin (Gibco, Grand Island, NY, USA). Cells were maintained at 37 1C/5% CO 2 .
To produce 4T1 tumors, BALB/c mice were orthotopically injected into the mammary fat pad with 10 6 cells suspended in 100 ml of phosphate-buffered saline (PBS). Experiments were performed 10 days after the tumor cell injection, before the tumors get highly necrotic and hemorrhagic (average tumor size: 300-500 mm 3 ). To produce MDA-MB-435 tumors, BALB/C athymic nude mice were injected into the mammary fat pad with 2 Â 10 6 cells in 100 ml of PBS, and the mice were used for experiments 4-6 weeks later (average tumor size: 500 mm 3 ). Before any surgical procedure, mice were anesthetized with intraperitoneal injections of xylazine (10 mg/kg) and ketamine (50 mg/kg). Animal experimentation was performed according to the procedures approved by the Animal Research Committees at the University of California, Santa Barbara.
Peptides and peptide-conjugated NWs
The peptides were synthesized as described .
Tetrameric peptides were obtained by conjugation with neutravidin (NA; Pierce, Rockford, IL, USA). NA was dissolved at 5 mg/ml in ultrapure water with 5% glycerol, heated to 37 1C for 1 h, sonicated and filtered. Biotinylated peptide stocks were prepared in water shortly before use, sonicated and added at equal volume to the NA for a final concentration of 250 mM peptide and 40 mM NA. Conjugates were used after 30 min with no additional purification.
NWs coated with peptides were prepared as previously described (Park et al., 2009; Agemy et al., 2010) .
In vitro phage binding and internalization Microtiter wells (Costar, Bloomington, MN, USA) were coated with 5 mg/ml of purified NRP1 or NRP2, blocked with PBS/0.5%. Bovine serum albumin and incubated with 10 8 plaque-forming units (p.f.u.) of phage in 100 ml of PBS/0.05% Tween 20 for 20 h at 37 1C. After six washes in PBS/0.05% Tween 20, bound phage was eluted with 200 ml of 1 M Tris-HCl (pH 7.5)/0.5% sodium dodecyl sulfate for 30 min and quantified by a plaque assay (titration).
To measure phage binding on cells, 2 Â 10 5 suspended cells were incubated with 7 Â 10 8 p.f.u./ml of T7 phage in Dulbecco's modified eagle medium/bovine serum albumin 1% for 1 h at 4 1C. Ligand-blocking antibodies or control goat IgG isotype (10 mg/sample) were added 30 min before phage incubation. The cells were washed four times with Dulbecco's modified eagle medium/bovine serum albumin 1%, and lysed with lysogeny broth/1% Nonidet P-40 (LB/NP40) before phage titration.
Phage, NW and peptide homing in vivo Normal BALB/c mice were intravenously injected with 10 10 p.f.u. of phage, which were allowed to circulate for 15 min. The mice were then perfused through the heart with PBS containing 1% Bovine Serum Albumin and tissues were collected and homogenized in 1 ml of LB/NP40 for titration.
4T1 tumor-bearing BALB/c mice and MDA-MB-435 tumor-bearing nude mice were intravenously injected with, respectively, 150 and 100 ml of 1 mM FAM-labeled synthetic peptides. After 1 h circulation, mice were perfused and tissues were collected, observed under blue light (Illumatool Bright Light System LT-9900, Lightools Research, Encinitas, CA, USA) and processed for immunofluorescence analysis.
Peptide-NWs (5 mg iron/kg mouse) were intravenously injected in 4T1 tumor-bearing mice and allowed to circulate for 30 min to 16 h. For co-injection experiments, a mixture of CGKRK-NWs (5 mg iron/kg mouse) and tLyP-1 peptide (1 mM) (peptide:peptide-NWs, 50:50) was intravenously injected in 4T1 tumor-bearing mice. After perfusion, organs were harvested and processed for immunofluorescence analysis.
Immunofluorescence Tissues were fixed with 4% paraformaldehyde and cryoprotected in 30% sucrose before OCT (optimal cutting temperature, Sakura, Torrance, CA, USA) embedding and freezing. Tissues were sectioned at 7 mm and stained with primary antibodies at 4 1C overnight. Secondary antibodies were incubated for 1 h at 37 1C. Stained tissue sections were mounted in Vectashield DAPI (4 0 ,6-diamidino-2-phenylindole)-containing mounting media (Vector Laboratories, Burlingame, CA, USA) and examined on a Fluoview 500 confocal microscope (Olympus America, Center Valley, PA, USA). To quantify the homing area of peptide-NWs, 10 fields/tumor cryosection were analyzed.
Cells were grown on collagen I-coated coverslips (BD Biosciences) for 24-72 h. After 4% paraformaldehyde fixation, cells were stained with antibodies following the same procedure as for tumor sections, and mounted in DAPI-containing mounting media. For phage binding assay, 10 9 p.f.u. of phage in cell culture medium were incubated for 1-2 h. When NApeptide inhibitors were used, they were added to the cell medium 30 min before phage incubation. NA alone, at the maximum concentration used in the assay, was used as a control. Cells were examined on a Fluoview 500 confocal microscope.
Statistical analysis
Data were analyzed by two-tailed Student's t-test.
